ClinicalTrials.gg
CompletedNCT07239973Updated Oct 13, 2026

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

A Phase 1 interventional study of BGM0504 tablets and Placebo tablets in Healthy and Non-diabetic Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Oct 13, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.

Enrollment
6th of 10
75 · median 78
Started
2025
with 5 others
Phase 1
6 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
8 of 10
BrightGene Bio-Medical Technology Co., Ltd.

Among the 10 studies testing BGM0504 in Obesity, this one is the 6th largest by enrollment, is one of 6 that started in 2025, is one of 6 in phase 1, and was the 8th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →

Where they have run

About BGM0504

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing BGM0504 in Obesity as a file.
02

Study summary

A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.

03

Conditions studied

  • Healthy
  • Non-diabetic Overweight or Obese

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages of 18 and 65 years (inclusive) at the time of screening , healthy and non-diabetic overweight or obese subjects , both male and female;
  • Healthy subjects , male weight ≥ 50 kg, female weight ≥ 45 kg, and (BMI): 20.0 kg/m² ≤ BMI \< 28 kg/m²(BMI = weight/height²);
  • Obese individuals: BMI ≥ 28.0 kg/m², or overweight individuals: 24.0 kg/m² ≤ BMI \< 28.0 kg/m²;
  • (Medical Inquiry) Have a stable body weight (\<5% self-reported change during the previous 12 weeks) before screening.
  • Have no history of mental disorders, be able to communicate smoothly with Investigator, Capable of understanding the written document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.
  • Male subjects with female partners of must agree to practice abstinence or to use a condom (male subject) plus an additional medically acceptable form of (female partner) for the duration of the study and for at least 3 months after dosing; must also agree to refrain from sperm donation for at least 3 months post dose

Exclusion criteria

Exclusion Criteria:

  • Those with a history of severe drug allergies (especially those with known or suspected allergies to the active ingredients and of BGM0504 Tablets), or complicated with severe specific allergic diseases/history, or with a severe allergic constitution.
  • Subjects with positive results for , anti-, anti- or anti-TP during the screening period.
  • At the screening/baseline period, any one of the laboratory test indicators meets the following criteria:

    1. fasting serum glucose≥ 7.0mmol/L, or post-prandial glucose (PPG)-2h≥ 11.1mmol/L in oral glucose tolerance test (OGTT); (During screening, participants with fasting serum glucose ranging from 6.1 to 6.9mmol/L shall undergo the OGTT.)
    2. , AST ≥ 2.5 times (ULN) or total ≥ 1.5 times upper limit of normal (ULN)
    3. (eGFR) ≤ 80 mL/min/1.73 m2(using CKD-EPI formula) or positive urine protein 2+ or more.
    4. Serum calcitonin level ≥ 35 ng/L (pg/mL);
    5. Thyroid-stimulating hormone (TSH) > 6.0mIU/L or \< 0.4mIU/L;
    6. Fasting triglycerides ≥ 5.64mmol/L (500 mg/dL);
    7. (Hgb) \< 100 g/L (for females) or \< 110 g/L (for males);
  • 12-lead shows ventricular heart rate \< 50 beats/min or > 100 beats/min at screening/baseline, second or third degree atrioventricular block, long syndrome, QTcF> 470ms for women or > 450ms for men, pre-excitation syndrome or other significant arrhythmias.
  • Used illegal drugs within 6 months prior to screening, or substance abuse within 12 months prior to screening.
  • Participated in drug or medical device clinical trials and treated with Study Drug (excluding placebo) or medical device intervention within 12 weeks before screening.
  • Participants who have received any vaccine within 2 weeks prior to screening, or plan to receive a vaccine during the trial.
  • Female participants who are pregnant or lactating, or those with a positive pregnancy test result during the screening period.
  • Positive urine drug test or alcohol serum test result at screening or at baseline.
  • Has any other conditions or disorders deemed unsuitable for including in the study, in the opinion of the Investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    BGM0504 tablets

    Oral administration once daily

    Drug: BGM0504 tablets

  • Experimental
    Placebo tablets

    Placebo Oral administration once daily

    Drug: Placebo tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Number of treatment adverse events

    The relationship of each adverse event to the investigational product was assessed by the investigator

    Time frame: 8 weeks

Secondary outcomes

  1. Pharmacokinetic endpoint: Concentration of BGM0504 in plasma

    Time frame: 8 weeks

  2. Change in fasting weight at week 8

    Time frame: 8 weeks

07

Study locations

1 site
  • The First Affiliated Hospital of Yunnan University of Chinese Medicine
    Kunming, Yunnan 650000, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Mar 2026, 4 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 20, 2025
StartActual
Oct 24, 2025
Primary completionActual
Mar 5, 2026
CompletionActual
Mar 5, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Start date
Oct 21, 2025→Oct 24, 2025
Oct 13, 2026
Primary completion
Mar 31, 2026→Mar 5, 2026 (actual)
Oct 13, 2026
Study completion
Mar 31, 2026→Mar 5, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    Start date Oct 21, 2025→Oct 24, 2025
    Primary completion Mar 31, 2026→Mar 5, 2026 (now actual)
    Study completion Mar 31, 2026→Mar 5, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07239973
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Oct 24, 2025
Primary completion
Mar 5, 2026
Completion
Mar 5, 2026
Last update
Oct 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion